Frequently
Asked
Questions
How do we participate?
If you are interested, speak with your child’s doctor. They can help determine if your child may be eligible and provide information about next steps. You may also explore whether your child or family member may be eligible by completing this form.
Why is there a randomized arm in the trial where some participants may receive a placebo?
To truly understand if ABS-1230 works, researchers need to compare ABS-1230 to a placebo (a substance with no active medicine). This helps researchers understand if changes in seizure activity are due to the medicine itself and not something else. To ensure study integrity, Part 2 participants and their doctor will not know if they received ABS-1230 or placebo.
All Part 2 participants, including those who received placebo, will have the opportunity to join an open-label long-term extension trial where everyone will receive ABS-1230.
Will this trial affect current medications?
Most participants may continue their existing seizure medications if doses have been consistent for approximately two months and will not be changed for the duration of the trial. However, some medications cannot be taken with ABS-1230 and may need to be safely stopped before trial participation begins, allowing time for the medications to fully clear from your system. Please consult your doctor prior to participation in the trial. Should you want to participate in the study, the trial team will monitor any medication changes closely.
Do we need to travel to a hospital?
This trial is decentralized, meaning trial visits happen at home through telemedicine, home nursing visits, and in-home EEG testing. You will have the option to go to a site in-person if that is preferred.
Who will cover the cost of participating in clinical trials, such as laboratory tests or travel?
The study sponsor, Actio Biosciences, will cover the cost of trial-related tests and procedures. Families will not be asked to pay for participation. Travel is minimal, with the majority of the trial being conducted remotely/from home.
If I, my family member, or my child is not eligible for the clinical trial, is Actio Biosciences able to provide compassionate use or expanded access?
Please see our expanded access policy.
When will ABS-1230 be available outside of the United States?
ABS-1230 is still in the early stages of clinical development. It is not yet approved or available outside of clinical trials in the U.S. Timelines for availability will depend on future trial results and approval by the U.S. FDA and other regulatory agencies.
Can my child travel to the U.S. to participate in this clinical trial?
We cannot guarantee enrollment for any individual patient. Clinical trial participation depends on a range of eligibility criteria as well as available trial sites and capacity. Additionally, participants must be located in the U.S. for the entire trial, including all visits and assessments.
Can I pay to participate in the trial?
Participation is voluntary and cannot involve payment in exchange for access to investigational treatments.
Could This Study Be Right for Your Family?
Answer a few quick questions to help us understand if your child might be eligible for the ABS-1230 clinical trial for KCNT1-related epilepsy.
This is not a formal enrollment form.
Your responses are confidential and will help our team connect you with more information.
KCNT1 Foundation
For more information about KCNT1-related epilepsy, new therapies in development, the latest research information and resources for families and caregivers, please visit the KCNT1 Epilepsy Foundation. The Foundation provides educational materials and a supportive community for families navigating this rare disease.